Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination

Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination

ABSTRACT The mesenchymal‐epithelial transition exon 14 (METex14) skipping mutation is a driver of non‐small cell lung cancer (NSCLC). MET tyrosine kinase inhibitors (TKIs), such as tepotinib, are effective against METex14 skipping‐positive NSCLC but carry a risk of acute exacerbation of interstitial...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshiki Kato, Takunori Ogawa, Kimiya Sato, Akira Matsukida, Akihiko Kawana, Ryosuke Nagaoka, Kotoba Esaki, Yoshifumi Kimizuka
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Respirology Case Reports
Subjects:
idiopathic pulmonary fibrosis
MET exon 14 skipping mutation
nintedanib
tepotinib
Online Access:https://doi.org/10.1002/rcr2.70241
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/rcr2.70241

Similar Items